Breast Cancer Clinical Trials Landscape

Curated by Dual Brain Lab (csilab.net) · Eleventh tumor type on the map Data cutoff: 2026-04 · Guideline anchor: NCCN Breast Cancer v2.2026 (Feb 27, 2026)

This post indexes all 86 landmark trials under /trials/breast/ into a full-view timeline, laid out along the 7-chapter skeleton of NCCN v2.2026. Breast cancer is the first tumor type on this site to introduce subtype-stratified narrative — §2 and §3 each split internally into three H3 tracks: HR+/HER2- / HER2+ / TNBC.

Quick entries by subtype:

→ HR+/HER2- (endocrine + CDK4/6 + PI3K/mTOR + SERD)
→ HER2+ (anti-HER2 + T-DXd + TKI)
→ TNBC / BRCA (IO + PARP + TROP2 ADC)

1. Clinical Landscape

The world’s largest female solid tumor. GLOBOCAN 2022: 2.3 M new cases and 670 k deaths worldwide, making breast cancer the #1 cancer in women globally. China’s 2022 NCCR data show ~400 k new cases (second only to lung cancer), with a notably lower mortality rate than the West — the combined result of early screening, standardized adjuvant care, and public-healthcare access.

Three subtypes, decades of groundwork. Breast is the first solid tumor to be opened up by molecular subtyping:

1975 — Jensen defines ER (estrogen receptor), establishing the HR+/HR- axis.
1987 — Slamon identifies HER2 overexpression; trastuzumab enters Phase I two years later; FDA approval in 1998 makes it the first targeted therapy for any solid tumor.
2005 — Perou proposes the PAM50 molecular subtype and the name TNBC (triple-negative breast cancer), locking in the modern HR / HER2 / TNBC three-pillar framework.

The 2023 re-stratification. In 2023, ASCO-CAP updated HER2 testing guidelines, renaming IHC 2+/1+ (FISH-negative) as HER2-low and adding HER2-ultralow (IHC > 0 but < 1+). The move directly brought the positive populations of DESTINY-Breast04 and DB06 — both trastuzumab deruxtecan (T-DXd) randomized trials — into the guidelines. “HER2-negative” is no longer a homogeneous population.

The rhythm of treatment. Breast cancer has gone through five paradigm shifts in the past 25 years:

Foundation era (1990s–2000) — tamoxifen / ATAC / HERA / NSABP B-31·N9831.
Anti-HER2 expansion (2000–2015) — trastuzumab → pertuzumab (CLEOPATRA) → T-DM1 (EMILIA / KATHERINE).
CDK4/6 × HR+ precision (2015–2025) — PALOMA / MONALEESA / MONARCH families × advanced 1L/2L × adjuvant extension (monarchE / NATALEE).
ADC reshaping (2020–2025, the headline act) — DESTINY-Breast 03/04/06/09 · ASCENT / TROPION-Breast02 · SHR-A1811 · RC48.
IO breakthrough (2020–2025) — KEYNOTE-522/355 · IMpassion130 · ASCENT-04 IO+ADC combos.

China’s pace. NMPA approvals of domestic or independent Phase IIIs from 2021–2025 include DAWNA-1/2 (dalpiciclib) · PHOEBE (pyrotinib vs lapatinib) · PHILA (pyrotinib + trastuzumab 1L HER2+) · SHR-A1811 (disitamab deruxtecan-like ADC) · RC48 (disitamab vedotin) · TORCHLIGHT (toripalimab + chemo 1L TNBC) · CAMBRIA (camrelizumab + chemo). In 2025, breast accounted for ~20% of new oncology approvals in China — the #2 most active tumor type.

Epidemiologic divergence drives treatment divergence. Chinese breast cancer has a median age of ~45–55 at diagnosis (vs 60–65 in the West), with a markedly higher share of premenopausal patients. This directly shapes: the OFS + AI vs tamoxifen premenopausal adjuvant pathway; the carboplatin threshold in neoadjuvant regimens; fertility-preservation and reproductive-endocrine counseling pathways; and the uptake of third-generation oral SERDs. China’s 1L breast cancer data now enter the global conversation as independent contributions, not merely as “confirmatory supplements” to international Phase IIIs.

Three drivers of falling mortality. Breast cancer mortality has dropped ~40% in the West and ~25% in China’s tier-1/2 cities over the past 30 years. Three stacked drivers: (1) early screening (mammography + MRI) has pushed the early-stage diagnosis share from ~30% to 60%+; (2) standardization of adjuvant therapy (5–10 years of endocrine + 1 year of anti-HER2 + individualized chemo) has lowered recurrence; (3) dense launches of late-stage drugs (CDK4/6 / T-DXd / sacituzumab / KEYNOTE-522 / OlympiA) have pushed median OS up another notch. The three-layer effect makes breast cancer the flagship for “early screening × standardization × innovative drugs” as a combined success story in oncology.

2024–2026 regulatory highlights.

2024-02 FDA — elacestrant (EMERALD) approved for ESR1mut 2L+ post-CDK4/6 HR+/HER2- mBC.
2024-06 FDA — capivasertib + fulvestrant (CAPItello-291) approved for HR+/HER2- mBC with AKT pathway alterations post-endocrine.
2024-10 FDA — inavolisib + palbociclib + fulvestrant (INAVO120) approved for PIK3CAmut HR+/HER2- mBC 1L.
2024-08 FDA — datopotamab deruxtecan (Dato-DXd, TROPION-Breast01) approved for HR+/HER2- mBC post-endocrine + 1 line chemo.
2024-09 FDA — T-DXd expansion into HER2-ultralow (IHC > 0 but < 1+) endocrine-resistant HR+/HER2- mBC (DESTINY-Breast06).
2025-Q1 NMPA — dalpiciclib + letrozole 1L HR+/HER2- mBC (DAWNA-2 supporting).
2025 ASCO — DESTINY-Breast09 topline: T-DXd + pertuzumab 1L HER2+ mBC vs CLEOPATRA backbone — challenging a ten-year standard.
2025 ESMO — ASCENT-04 sacituzumab govitecan + pembrolizumab 1L mTNBC PD-L1+ data matures.
2025 SABCS — SERENA-6 camizestrant ctDNA-guided switch is positive — the first Phase III proof of ctDNA-guided precision therapy in breast cancer.

2. Current Treatment Paradigms

Breast cancer treatment must be laid out by molecular subtype — the drug arsenal is almost entirely non-overlapping across the three types: HR+/HER2- centers on the endocrine backbone; HER2+ on the anti-HER2 backbone; TNBC has only chemo + IO + PARP + ADC. This chapter walks through all three.

HR+/HER2-

Share and backbone. HR+/HER2- is about 65–70% of breast cancer — the largest subtype. The backbone has gone through four generations of layering: endocrine (SERM / AI / fulvestrant) → CDK4/6 inhibitor addition → PI3K/mTOR/AKT pathway drugs keyed to mutations → oral SERD (selective estrogen receptor degrader) as the newest layer.

The endocrine backbone. ATAC (2010) established anastrozole’s adjuvant advantage in postmenopausal ER+ early breast cancer — 10-year DFS 79.9% vs tamoxifen 77.6%. MA.17 / MA.17R extended letrozole into a 10-year AI regimen, supporting extended adjuvant in high-risk postmenopausal patients. ATLAS (2013) extended tamoxifen adjuvant from 5 to 10 years, establishing the extension strategy for premenopausal women or those intolerant of AIs. The twin trials SOFT / TEXT established the DFS benefit of “ovarian function suppression (OFS) + AI” in high-risk premenopausal patients. This endocrine backbone remains, as of 2026, the foundation for the vast majority of HR+/HER2- patients.

CDK4/6 enters the late-stage setting. From 2015 to 2020, three CDK4/6 inhibitors arrived almost in lockstep:

Palbociclib — PALOMA-2 (1L + letrozole) and PALOMA-3 (fulvestrant + palbo 2L), establishing the 2L endocrine + CDK4/6 standard.
Ribociclib — MONALEESA-2 (postmenopausal 1L) · MONALEESA-3 (fulvestrant combo) · MONALEESA-7 (premenopausal + OFS), the unique trio that delivered an OS benefit.
Abemaciclib — MONARCH-2 (fulvestrant 2L) · MONARCH-3 (1L), showing OS advantage.

All three pushed median PFS from endocrine mono’s 9–14 months up to 24–28 months — the deepest single reshape of the HR+/HER2- metastatic landscape.

CDK4/6 extends into the adjuvant setting. monarchE (abemaciclib × 2 years, for N+ ≥ 4 or 1–3+ with high-risk features) and NATALEE (ribociclib × 3 years, for node-any including stage IIA) carried CDK4/6 from advanced into adjuvant. The two trials differ in enrollment breadth, follow-up duration, and DFS HR — creating a real clinical-choice tension in 2026 (see §3).

PI3K / AKT / mTOR precision.

PIK3CA mutation → SOLAR-1 (alpelisib + fulvestrant) · INAVO120 (inavolisib + palbo + fulvestrant, 2024 NEJM, mPFS 15.0 vs 7.3 months).
AKT pathway (PIK3CA / AKT1 / PTEN mutations) → CAPItello-291 (capivasertib + fulvestrant, 2023 NEJM, mPFS 7.3 vs 3.1 months).
mTOR pathway → BOLERO-2 (everolimus + exemestane) as the historical cornerstone.

The oral SERD era.

EMERALD (elacestrant 2L post-CDK4/6, ESR1mut subgroup mPFS 3.8 vs 1.9 months) is the first oral SERD to win approval.
SERENA-6 (camizestrant ctDNA-guided ESR1mut switch, 2024) shows the precision-adjust pattern: detect resistance early via ctDNA → switch drugs preemptively.
EMBER-3 (imlunestrant ± abemaciclib, 2024 NEJM) opens options via its multi-arm design.
PADA-1 was the early proof-of-feasibility for ESR1mut-driven switching.

China’s contribution. DAWNA-1 / DAWNA-2 (dalpiciclib + fulvestrant, 2L post-CDK4/6) build a domestic data chain with China’s own CDK4/6i. postMONARCH (2024 SABCS) repositions abemaciclib for continued use after CDK4/6 resistance. BG01-2201L is a domestic oral SERD data extension.

2026 HR+/HER2- decision tree skeleton:

Premenopausal low-risk N0 early → tamoxifen 5–10 years (ATLAS) or OFS + AI (SOFT/TEXT high risk).
Postmenopausal early HR+/HER2- → AI 5 years + extension (MA.17R / ATAC).
N+ ≥ 4 or 1–3+ with high-risk features → adjuvant abemaciclib × 2 years (monarchE) or ribociclib × 3 years (NATALEE) on top of the endocrine backbone.
Advanced 1L HR+/HER2- → CDK4/6i + endocrine (any of palbo / ribo / abema, chosen by access + toxicity profile).
1L PIK3CAmut → INAVO120 inavolisib + palbo + fulv (2024 SABCS positive).
2L post-CDK4/6 → three branches by biomarker: ESR1mut → elacestrant / camizestrant (EMERALD / SERENA-6) · PIK3CAmut → alpelisib (SOLAR-1) · AKT pathway → capivasertib (CAPItello-291) · all negative → everolimus (BOLERO-2).

HER2+

Share and groundwork. HER2+ is about 15–20% of breast cancer. The 25-year treatment history is oncology’s most complete precision-therapy narrative arc — from trastuzumab to T-DXd, each of four drug generations pushed mortality risk down another notch.

Anti-HER2 backbone (adjuvant).

HERA (2005 NEJM, trastuzumab × 1 year adjuvant vs observation) and NSABP B-31 / NCCTG N9831 joint analysis rewrote the HER2+ early post-op standard in 2005, with DFS HR ~0.5–0.6.
BCIRG-006 (docetaxel + carbo + trastuzumab, TCH regimen) provided an anthracycline-sparing alternative.
APHINITY (pertuzumab added to trastuzumab + chemo adjuvant, 2017 NEJM) delivered iDFS benefit in high-risk (N+) subgroups — marginal in low-risk.
APT (2015 NEJM, low-risk T1N0 HER2+, paclitaxel + trastuzumab × 12 weeks adjuvant) set a de-escalation precedent — 7-year iDFS 93%.
ATEMPT (T-DM1 adjuvant vs THx in low-risk HER2+) — T-DM1 is an option in low-risk, but toxicity doesn’t favor it.
ExteNET (neratinib extended adjuvant) — marginal benefit in the HR+/HER2+ subgroup, use limited by toxicity.

Neoadjuvant standard.

NeoSphere (pertuzumab + trastuzumab + docetaxel neoadjuvant, pCR 45.8% vs 29%) is the proof-of-concept for dual-target neoadjuvant therapy.
TRYPHAENA (TCHP regimen safety) supports the regimen’s feasibility.
KRISTINE (T-DM1 + pertuzumab neoadjuvant vs TCHP) — the T-DM1 arm’s pCR was lower than TCHP (44% vs 56%), so TCHP remains the neoadjuvant first choice.
KATHERINE (2019 NEJM) is the inflection point for HER2+ neoadjuvant residual disease: in non-pCR patients, switching to T-DM1 vs continuing trastuzumab yielded iDFS HR 0.50, splitting adjuvant into two tracks: “pCR → trastuzumab / non-pCR → T-DM1”.

Advanced HER2+, 1L to 2L.

CLEOPATRA (Baselga 2012 NEJM PFS + Swain 2015 NEJM OS, pertuzumab + trastuzumab + docetaxel 1L mBC, mOS 56.5 vs 40.8 months, HR 0.68) has been the HER2+ advanced 1L standard for a full decade.
PHILA (pyrotinib + trastuzumab + docetaxel vs placebo + TH, China 2024) gives a domestic pan-HER TKI a 1L pathway.
EMILIA (T-DM1 2L vs lapatinib + capecitabine) · TH3RESA (T-DM1 3L+) established T-DM1’s position in anti-HER2 2L+.
MARIANNE (T-DM1 ± pertuzumab vs THx 1L) was negative on its primary endpoint — T-DM1 not recommended in 1L.
EGF104900 (lapatinib + trastuzumab dual-target vs lapatinib monotherapy) was the early evidence of dual-blockade advantage.
DESTINY-Breast03 (2022 NEJM, T-DXd vs T-DM1 in 2L HER2+ mBC, mPFS 28.8 vs 6.8 months, HR 0.33; OS HR 0.64) fully rewrote the 2L standard — T-DM1 in 2L now occupies only the “T-DXd unavailable / intolerable” slot.
DESTINY-Breast02 (T-DXd vs TPC post-T-DM1 resistance) confirmed T-DXd’s benefit in later lines.
DESTINY-Breast09 (T-DXd ± pertuzumab 1L HER2+ mBC, 2025 ASCO / NEJM) is challenging CLEOPATRA’s ten-year iron throne.

The CNS / brain metastasis line. HER2+ has a high brain-met risk (~30–50% of advanced patients), spawning an independent treatment line:

HER2CLIMB (2020 NEJM, tucatinib + trastuzumab + capecitabine vs TPC) is the first Phase III with intracranial PFS data in active brain metastases.
TUXEDO-1 — T-DXd in active brain mets, small Phase II positive.
DEBBRAH — T-DXd brain-met evidence.
PHENIX (pyrotinib + capecitabine 2L China 2019 Lancet Oncology) · PHOEBE (pyrotinib vs lapatinib 2L+ China 2021 Lancet Oncology) fill in the brain-met data for domestic TKIs.

The ADC new wave. Beyond T-DXd, China-originated ADCs are entering HER2+ later lines:

SHR-A1811-102 — Phase II HER2+ post-T-DM1 evidence for SHR-A1811 (a domestic HER2 ADC with topoisomerase payload).
HOPES — a China 2021 reinforcement of HER2+ TKI + chemo data.
RC48-C006 — RC48 (disitamab vedotin, China’s first domestic ADC) expanding HER2+ urothelial / breast indications.

2026 HER2+ decision tree skeleton:

Stage I T1N0 low-risk → adjuvant paclitaxel + trastuzumab × 12 weeks (the APT de-escalation path).
Stage II-III node+ high-risk → neoadjuvant TCHP × 6 cycles → surgery → if pCR, trastuzumab + pertuzumab to complete 1 year (APHINITY); if non-pCR, switch to T-DM1 × 14 cycles (KATHERINE).
Advanced 1L HER2+ mBC → pertuzumab + trastuzumab + docetaxel (CLEOPATRA, the ten-year standard); if DB09 confirms positive, may shift toward T-DXd + pertuzumab.
2L HER2+ mBC → T-DXd (established by DESTINY-Breast03).
3L+ HER2+ mBC → tucatinib + trastuzumab + capecitabine (HER2CLIMB, the first choice for active brain mets) · T-DM1 (retained for T-DXd-unavailable situations) · neratinib · lapatinib + cape · margetuximab.
Active brain mets → HER2CLIMB (tucatinib-based) or T-DXd (TUXEDO-1 / DEBBRAH).

TNBC

Share and genetics. TNBC is 10–15% of breast cancer — younger, more aggressive, with common brain / visceral metastasis; germline BRCA1/2 is enriched (~15–20% of TNBC). The four therapeutic cards are chemo + IO + PARP + ADC.

Chemotherapy backbone.

GeparSixto (2014 Lancet Oncology) · CALGB-40603 (2015 JCO) laid the evidentiary foundation for adding carboplatin to neoadjuvant TNBC chemotherapy — pCR improved, though DFS benefit had to be stratified in later trials.
BEATRICE (bevacizumab adjuvant TNBC) was negative on primary endpoint; bev is not considered for adjuvant.
BrighTNess (carbo + veliparib + paclitaxel neoadjuvant) validated the carbo pCR benefit; veliparib added no incremental value.

IO enters (the pivotal inflection).

IMpassion130 (2018 NEJM, atezolizumab + nab-paclitaxel 1L mTNBC, PD-L1+ subgroup mOS 25.0 vs 15.5 months) brought IO into mTNBC 1L for the first time — but IMpassion131 (paclitaxel backbone) failed to reproduce, creating tension in the choice of chemo backbone.
KEYNOTE-355 (2020 NEJM → 2022 final, pembrolizumab + chemo 1L mTNBC, CPS ≥ 10 subgroup mPFS 9.7 vs 5.6 months, mOS 23 vs 16 months) established pembro + chemo as the CPS ≥ 10 mTNBC 1L standard.
KEYNOTE-522 (2020 NEJM → 2024 EFS/OS, pembrolizumab + chemo neoadjuvant → pembro adjuvant in stage II-III TNBC, pCR 64.8% vs 51.2%, EFS HR 0.63, OS HR 0.66) pushed IO into TNBC early adjuvant — without PD-L1 screening.
KEYNOTE-119 (pembrolizumab monotherapy vs chemo 2L+ mTNBC) — negative; IO monotherapy 2L+ is not approved.
KEYNOTE-158 (pembrolizumab tumor-agnostic MSI-H) — TNBC subgroup evidence supports the MSI-H basket.
GeparNuevo (durvalumab + neoadjuvant chemo) — German Phase II that paved the way for KN-522.
IMpassion031 (atezolizumab + chemo neoadjuvant TNBC) — pCR benefit supported.

PARP enters.

OlympiAD (2017 NEJM, olaparib 2L+ germline BRCA1/2 mBC, mPFS 7.0 vs 4.2 months).
EMBRACA (2018 NEJM, talazoparib 2L+ gBRCA mBC).
OlympiA (2021 NEJM, olaparib × 1 year adjuvant gBRCA HER2- high-risk, iDFS HR 0.58, OS HR 0.68) is the dawn of the BRCA-targeted adjuvant era, pushing PARP from “germline BRCA advanced 2L” into adjuvant.

TROP2 ADC enters.

ASCENT (2021 NEJM, sacituzumab govitecan 2L+ mTNBC, mPFS 5.6 vs 1.7 months, mOS 12.1 vs 6.7 months, HR 0.48) is the TROP2 ADC cornerstone in mTNBC 2L+.
TROPION-Breast02 (datopotamab deruxtecan, 2025 ASCO) — Dato-DXd in mTNBC 1L vs TPC, expanding the TROP2 ADC footprint.
ASCENT-04 (sacituzumab govitecan + pembrolizumab 1L mTNBC PD-L1+) — early readout of an IO + ADC combo.

PI3K/AKT in TNBC. LOTUS (ipatasertib + paclitaxel 1L mTNBC) · PAKT (capivasertib + paclitaxel 1L mTNBC) provided the early AKT-inhibition signal in TNBC; after CAPItello-291’s approval in HR+/HER2-, the TNBC direction remains unsettled.

China’s contribution. TORCHLIGHT (toripalimab + nab-paclitaxel 1L mTNBC, China 2023 Nature Medicine) · CAMBRIA (camrelizumab + chemo neoadjuvant) · FUTURE-SUPER (Fudan umbrella trial matching treatment to the LAR / IM / BLIS / MES four-subtype classification) · NeoTRIP (atezolizumab neoadjuvant) form China’s TNBC data line. The LAR / BL1 / IM / MES four-subtype classification (Fudan Shao’s team) is the international-grade original contribution from China to TNBC molecular subtyping.

2026 TNBC decision tree skeleton:

Stage II-III TNBC neoadjuvant → pembrolizumab + carbo + taxane → AC → surgery → complete 1 year of pembro (KEYNOTE-522, no PD-L1 screening).
Non-pCR residual → capecitabine adjuvant (CREATE-X logic) · if gBRCA+, olaparib × 1 year adjuvant (OlympiA).
Stage I T1N0 TNBC → dose-dense AC-T or carbo-taxane; IO adjuvant is not yet covered.
Advanced 1L mTNBC → first check CPS (22C3 assay): CPS ≥ 10 → pembrolizumab + chemo (KEYNOTE-355) · CPS < 10 and gBRCA+ → talazoparib / olaparib (EMBRACA / OlympiAD) · otherwise → chemo (paclitaxel or eribulin).
2L+ mTNBC → sacituzumab govitecan (ASCENT, TROP2 ADC, no screening required) · if gBRCA+ and PARP-naive, PARP is still an option.
Post-resistance → Dato-DXd (TROPION-Breast02, pending approval) · ASCENT-04 IO + ADC combinations in later lines.

3. Current Controversies

Each subtype has its own “top unsolved questions”. Writing them separately by subtype reveals the tension points more clearly than mixing them together.

HR+/HER2-

CDK4/6 adjuvant coverage debate. monarchE restricts to node ≥ 4 or 1–3+ with high-risk features (Ki67 / grade / tumor size), abemaciclib × 2 years; NATALEE covers stage IIA-III node-any, ribociclib × 3 years. NATALEE’s broader enrollment brings in low-risk node+ patients, but the absolute benefit is smaller and the toxicity exposure longer. The 2026 clinical tension: how heavily should individual-risk tools (Oncotype / MammaPrint / Ki67) weigh into first-line and adjuvant decisions? NCCN v2.2026 recommends both in parallel, individualized to the patient’s risk profile and expected tolerability.

The sequencing war in endocrine resistance. ESR1mut → elacestrant (EMERALD) · PIK3CAmut → alpelisib (SOLAR-1) / inavolisib (INAVO120) · AKT pathway → capivasertib (CAPItello-291) — three molecular branches whose ordering is debated: by ctDNA detection order + prior therapy, or by mutation priority? SERENA-6’s ctDNA-guided switch tentatively supports “switch immediately once ESR1mut appears”; the path for AKT / PIK3CA double-positives still lacks randomized evidence.

Continue CDK4/6 after CDK4/6 resistance? postMONARCH (2024 SABCS) showed marginal PFS benefit (mPFS 6.0 vs 5.3 months) for abemaciclib + fulvestrant after CDK4/6 resistance — is this clinically meaningful enough to continue, or should patients switch to SERD / PI3K/AKT directly?

TAILORx / RxPONDER re-stratification. TAILORx (2018 NEJM) used Oncotype DX in N0 HR+ to spare patients with Recurrence Score 11–25 from adjuvant chemo — a paradigm of genomic testing as a decision tool. RxPONDER (2021 NEJM) applied Oncotype in N1 HR+ and found premenopausal vs postmenopausal populations benefit differently: premenopausal N1 derives significant chemo benefit, postmenopausal does not. The 2026 real-world tension is the accessibility and cost of Oncotype at Chinese county hospitals — can clinical-pathologic surrogates substitute?

Adjuvant CDK4/6 vs extended endocrine — cost effectiveness. monarchE’s 2-year abemaciclib total cost, adverse events (diarrhea / VTE / fatigue management), and real-world compliance (most patients cannot adhere for 2 full years) — compared to the low-cost strategy of extending AI from 5 to 10 years (MA.17R) — is the marginal iDFS benefit worth it? This debate has different answers in regions with different reimbursement coverage (Japan / Korea vs West).

SONIA’s reverse question. SONIA (Phase III, 2024 JAMA) ran a head-to-head on whether CDK4/6 belongs in 1L or 2L: 1L endocrine mono → progression → 2L CDK4/6 vs 1L CDK4/6 + endocrine → 2L endocrine. SONIA’s primary endpoint PFS2 (cumulative PFS over two lines) showed no significant difference — suggesting that for lower-burden HR+/HER2- mBC, CDK4/6 can be delayed. Whether 2026 clinical practice accepts this “delayed” strategy remains contested.

HER2+

HER2-low / HER2-ultralow boundaries. After the ASCO-CAP 2023 reclassification: HER2-low (IHC 1+ or 2+/FISH-) was approved via DESTINY-Breast04 (2022 NEJM, T-DXd vs TPC, HR+ subgroup mPFS 10.1 vs 5.4 months / HR 0.51); HER2-ultralow (IHC > 0 but < 1+) via DESTINY-Breast06 (2024 NEJM, T-DXd vs TPC 1L HR+ endocrine-resistant), pushing T-DXd further upstream and expanding into ultralow. The traditional “HER2-negative” label is essentially dismantled in 2026 — only HER2 IHC 0 with FISH-negative remains as true-negative, treated TNBC-like. The real clinical tension is HER2-low vs ultralow detection reproducibility + pathology report workflow. China-originated ADCs MRG002 (2024 SABCS) · SHR-A1811-HER2low (Phase II) are also pushing through this window.

Will adjuvant T-DXd replace KATHERINE? KATHERINE (2019 NEJM) replaced trastuzumab with T-DM1 as the adjuvant for non-pCR patients after neoadjuvant — only 6 years ago. DESTINY-Breast05 (T-DXd vs T-DM1 adjuvant non-pCR high-risk HER2+, ongoing) · DB11 (T-DXd adjuvant in earlier stages) — if these are positive, the T-DM1 adjuvant standard will hand over in 2027–2028.

TCHP vs AC-THP neoadjuvant choice. Whether anthracycline-sparing is safe in node-positive HER2+ still has marginal debate. BCIRG-006 supports the TCH / TCHP pathway, but some high-risk patients are still directed to AC-THP. NCCN 2026 recommends both in parallel, individualized by cardiac risk + pCR goals + tumor burden.

Pertuzumab in low-risk — benefit dispute. APHINITY’s primary endpoint was positive but overall benefit was marginal (iDFS HR 0.81), with the real benefit concentrated in N+ or high-risk node- subgroups. Do low-risk N0 HER2+ patients need dual-target? The APT de-escalation pathway says no — T+H × 12 weeks of paclitaxel alone is enough. In 2026 clinical practice, the cutoff is at T1c N0: T1c+ gets TCHP; T1ab N0 low-risk uses the APT simplified regimen.

HER2+ BC brain-met screening strategy. HER2+ mBC has a 30–50% brain-met rate — should baseline MRI be done at metastatic diagnosis? NCCN 2026 recommends a lower threshold for MRI beyond symptom-driven. HER2CLIMB / TUXEDO-1 / DEBBRAH all support the early-detection-and-active-treatment strategy, but the cost-effectiveness of asymptomatic screening remains contested.

CLEOPATRA’s ten-year standard challenged by DESTINY-Breast09. If DB09’s T-DXd ± pertuzumab 1L confirms OS benefit, the HER2+ mBC 1L standard will shift from “pertuzumab + trastuzumab + docetaxel (CLEOPATRA)” to “T-DXd + pertuzumab” — but ADC early toxicity management (ILD interstitial lung disease ~10%) + CNS activity comparison are the two branching debates.

TNBC / BRCA

IO biomarker thresholds aren’t unified. KEYNOTE-522 (neoadjuvant) doesn’t screen PD-L1 — all-comers use; KEYNOTE-355 (1L mTNBC) requires CPS ≥ 10; KEYNOTE-119 (2L+) was negative. Same drug, different thresholds across settings — is the tumor immune microenvironment more active in early stage? Or is pCR a more sensitive surrogate?

The IMpassion130 vs IMpassion131 backbone mystery. Atezolizumab + nab-paclitaxel was positive (IMpassion130), + paclitaxel was negative (IMpassion131). Possible reasons: pre-medication steroid impact on IO response, nab chemo’s own immunomodulatory effects, sample PD-L1 distribution differences — no head-to-head RCT resolved this. Atezolizumab’s use script has narrowed in most Western guidelines.

germline BRCA-only for PARP, reasonable? OlympiA cemented germline BRCA1/2 adjuvant PARP, but can somatic BRCA / HRD-positive TNBC be extrapolated? Current evidence is insufficient; NCCN strictly restricts to germline + high-risk. The clinically common “hereditary + sporadic double-positive” subgroup lacks evidence.

LAR / BL1 / IM / MES molecular subtype’s clinical translation. Fudan Shao’s team TNBC four-subtype (LAR luminal androgen receptor · BL1 basal-like 1 · IM immunomodulatory · MES mesenchymal) has been validated in Chinese umbrella trials FUTURE-SUPER / FUTURE-C-PLUS. International acceptance is incomplete; in 2026, this remains a China-led candidate framework for TNBC precision therapy.

ASCENT-04 vs ASCENT sequencing. After using sacituzumab govitecan + pembrolizumab in 1L, how should 2L+ connect the ADC / IO chain? TROPION-Breast02 / ASCENT-04 / KN-522 — the three-axis sequencing is still being figured out.

KN-522 adjuvant pembro timing. KEYNOTE-522 runs 1 year of pembro throughout; do patients achieving pCR still need the full adjuvant IO? A de-escalation trial analogous to HER2+’s “pCR → T-DM1 downshift / non-pCR → T-DM1 upshift” is being designed for TNBC, but no Phase III readout yet.

Capecitabine CREATE-X path vs PARP OlympiA path. For non-pCR TNBC residual disease, choose capecitabine adjuvant (CREATE-X logic) or olaparib (gBRCA+ subset)? For the mixed “gBRCA+ non-pCR TNBC” patient, which should be prioritized? Sequential or parallel? Evidence is lacking.

FUTURE-SUPER / Fudan subtyping’s international acceptance. LAR / BL1 / IM / MES was proposed by the Fudan Zhongshan Hospital Shao team in 2019, paired with the FUTURE-SUPER umbrella trial that matches treatment to subtype: LAR → anti-androgen · IM → IO + chemo · BLIS → chemo intensification · MES → VEGF/EGFR pathway. International guidelines (NCCN / ESMO) have not adopted it as of 2026 — main concerns: subtype reproducibility, RNA-seq panel accessibility, subtype switching rate (the same tumor biopsied multiple times may yield different subtypes). But this is China’s most original contribution to breast cancer precision therapy, and 2027–2028 international replication is worth watching.

ADC-naive vs ADC-exposed resistance mechanisms differ. Sacituzumab govitecan and Dato-DXd both target TROP2, but payload differences (SN-38 vs DXd) may shape different resistance mechanisms. After T-DXd enters HER2-low, if HER2-null reappears, can patients return to the TNBC path via TROP2 ADC? Or does TROP2 downregulate simultaneously? This sequencing lacks systematic real-world molecular data.

4. Biomarker Framework

Breast cancer’s biomarker panel is the most complete and earliest-established of all solid tumors. In 2026, a newly diagnosed breast cancer needs a minimum panel of at least 8 items:

Core typing:

HR (ER / PR) — classic binary classification since the 1990s; ER+ PR+ double-positive vs ER+ alone stratifies endocrine sensitivity.
HER2 — IHC 4 tiers (0 / 1+ / 2+ / 3+) + FISH; ASCO-CAP 2023 added HER2-low (IHC 1+ or 2+/FISH-) and HER2-ultralow (> 0 but < 1+). The four tiers map to treatment branches: 3+ → anti-HER2; 2+/FISH+ → anti-HER2; 1+ or 2+/FISH- → HER2-low (DB04 / DB06); ultralow → DB06.
PAM50 intrinsic subtype (Luminal A / B · HER2-enriched · Basal-like · Normal-like) is increasingly used in adjuvant decisions and CDK4/6 adjuvant extension. Oncotype DX / MammaPrint / Prosigna are clinical surrogates.

Endocrine resistance + precision targeting:

ESR1 mutation — endocrine resistance marker, sensitive to SERDs (elacestrant / camizestrant); ctDNA dynamic detection has become SERENA-6’s gating biomarker.
PIK3CA mutation — the biomarker for SOLAR-1 alpelisib / INAVO120 inavolisib, present in ~40% of HR+/HER2- patients.
AKT1 / PTEN mutation — the extension biomarker for CAPItello-291 capivasertib.
BRCA1/2 germline / somatic / HRD score — mandatory for PARP (olaparib / talazoparib); all HER2- breast cancers should have germline testing.

ADC targets:

TROP2 — broadly expressed across breast cancer; no clinical screening required for sacituzumab govitecan / Dato-DXd.
HER2 payload-aware — HER2-low / ultralow detection is critical for T-DXd / SHR-A1811 / MRG002 use.

Immunotherapy:

PD-L1 CPS — KEYNOTE-355 CPS ≥ 10 (22C3 assay) gates 1L mTNBC pembro; Ventana SP142 is the assay-difference source for atezolizumab positivity.
Stromal TILs — strong neoadjuvant pCR predictor; not used for treatment decisions in 2026.

Uncommon but critical:

MSI-H / dMMR — < 2% incidence in breast cancer but KEYNOTE-158 tumor-agnostic applies.
NTRK fusion — < 1%; larotrectinib / entrectinib tumor-agnostic applies.
AR (androgen receptor) — LAR subtype (Fudan classification) biomarker; enzalutamide / bicalutamide in TNBC LAR subgroup clinical exploration.
ctDNA dynamics — SERENA-6 pushed ctDNA from a prognostic marker to a treatment-switching trigger — 2026 marks breast cancer’s entry into ctDNA-guided decision-making with first Phase III proof.

The 2026 reality of biomarker testing. IHC stability in lumpectomy specimens remains the bottleneck for HER2-low / ultralow deployment — different pathologists have limited agreement on IHC 0 vs 1+ and 1+ vs 2+ (kappa ~0.6); the same specimen sliced at different times may cross tiers on retest. Clinical practice recommends: before T-DXd decision, repeat IHC (at least two independent pathology reports) + confirm score boundary judgment. Future pan-HER2 quantitative assays (HERmark / digital quantitative IHC) may replace the current 4-tier system.

5. Time-Space Overview

Five paradigms laid out in parallel, 1990–2025. Mapping the 86 landmark trials by paradigm + year produces five parallel evolutionary tracks:

① Foundation era (1990–2000): endocrine + anti-HER2 grounded in parallel

1996 — NSABP B-14 (tamoxifen adjuvant ER+)
1998 — trastuzumab FDA approval (first targeted drug for any solid tumor)
2002 — ATAC (anastrozole vs tamoxifen, postmenopausal adjuvant)
2005 — HERA / NSABP B-31 / N9831 (trastuzumab × 1 year adjuvant HER2+)

② Anti-HER2 expansion (2005–2015): pertuzumab + T-DM1 complete the back-line arsenal

2011 — NeoSphere (dual-target + docetaxel neoadjuvant HER2+)
2012 — EMILIA (T-DM1 2L HER2+ mBC)
2012 — CLEOPATRA (pertuzumab + trastuzumab + docetaxel 1L HER2+ mBC)
2013 — APHINITY enrolls (pertuzumab added to adjuvant HER2+)
2015 — APT (low-risk HER2+ T+H de-escalation × 12 weeks)
2019 — KATHERINE (non-pCR → T-DM1 adjuvant)

③ CDK4/6 × HR+ precision (2015–2025): advanced 2L and adjuvant extension

2016–2019 — PALOMA-1/2/3 · MONALEESA-2/3/7 · MONARCH-2/3 (the three CDK4/6 families)
2018 — TAILORx (Oncotype DX N0 chemo sparing)
2020 — SOLAR-1 (alpelisib PIK3CAmut 2L)
2021 — RxPONDER · monarchE (abema adjuvant N+ high risk)
2023 — NATALEE (ribo adjuvant node-any) · CAPItello-291 (capivasertib AKT) · EMERALD (elacestrant ESR1mut)
2024 — INAVO120 (inavolisib + palbo + fulv) · SERENA-6 (ctDNA-guided switch) · EMBER-3 (imlunestrant) · DAWNA-2

④ ADC reshaping (2020–2025, the headline act): T-DXd + TROP2 ADC dual axis

2021 — ASCENT (sacituzumab govitecan 2L+ mTNBC) · DESTINY-Breast01 (T-DXd 2L+ HER2+ mBC accelerated)
2022 — DESTINY-Breast03 (T-DXd vs T-DM1 2L HER2+, mBC standard inflection) · DESTINY-Breast04 (T-DXd in HER2-low)
2023 — DESTINY-Breast02 (T-DXd post-T-DM1)
2024 — DESTINY-Breast06 (HER2-ultralow T-DXd 1L endocrine-resistant)
2025 — DESTINY-Breast09 (T-DXd + pertuzumab 1L HER2+, CLEOPATRA challenger) · TROPION-Breast02 (Dato-DXd 1L mTNBC) · ASCENT-04 (sacituzumab + pembro 1L mTNBC) · SHR-A1811 / MRG002 / RC48 (China-originated ADCs)

⑤ IO breakthrough (2020–2025): TNBC + early adjuvant

2018 — IMpassion130 (atezo + nab-pac 1L mTNBC PD-L1+)
2020 — KEYNOTE-522 (pembro + chemo neoadj → adj stage II-III TNBC) · KEYNOTE-355 (pembro + chemo 1L CPS ≥ 10)
2021 — OlympiA (olaparib adjuvant gBRCA HER2- high risk)
2023 — TORCHLIGHT (toripalimab + nab-pac 1L mTNBC, China)
2024 — KEYNOTE-522 EFS/OS final · ASCENT-04 IO+ADC

Clinical read-out of the five lines in parallel. In 2026, the decision tree for any newly diagnosed breast cancer patient = subtype triage (① endocrine / ② HER2 / ③ TNBC) → stage pathway (neoadj / adj / advanced) → biomarker panel (HR / HER2 four-tier / PIK3CA / BRCA / CPS) → paradigm assignment. No single paradigm dominates alone — they layer in parallel.

Vertical cross-section along the five paradigms. The adjuvant plan for the same “HR+ N+ HER2+ stage II female” patient — 2000 vs 2026:

2000 could offer: AC × 4 chemo + tamoxifen × 5 years + trastuzumab (available in a few centers after 1998 approval).
2026 can offer: pre-op MRI + neoadjuvant TCHP × 6 cycles → surgery → if pCR, T+P to complete 1 year / if non-pCR, switch to T-DM1 × 14 cycles → adjuvant AI + OFS × 5 years → if high-risk, add monarchE / NATALEE CDK4/6 → extend AI to 10 years.

In 26 years, the same patient’s adjuvant cycle has extended from ~6 months to ~24–36 months; drug categories from 3 to 8–10; 10-year OS from ~85% to ~93%. This is the miniature of oncology’s precision-stratification era.

Vertical × horizontal: the 2026 landscape is shaped by four-way resonance

Overlaying the five paradigms with three subtypes, the 2026 breast cancer landscape is the product of four-way resonance:

HR endocrine backbone (30 years) + CDK4/6 (2015–2020) + precision drugs (2020–2026, SERD / PI3K / AKT / mTOR) — pushed HR+/HER2- 1L mPFS from endocrine mono’s 9–14 months to CDK4/6 combo’s 24–28 months, then to INAVO120 / SERENA-6 ctDNA-guided precision increments.
Anti-HER2 four generations (trastuzumab → pertuzumab → T-DM1 → T-DXd) — rewrote the HER2+ “death sentence” from 1998’s “1-year OS ~30%” to 2025’s “metastatic 1L mOS ~57 months” (CLEOPATRA); T-DXd + DB03/04/06/09 extended into HER2-low / ultralow.
TNBC IO breakthrough (2020 KEYNOTE-522) + TROP2 ADC (2021 ASCENT) + PARP adjuvant (2021 OlympiA) + China’s molecular subtyping (Fudan Shao’s LAR/BL1/IM/MES) — pushed TNBC from “only chemo” to four co-constructed treatment axes.
ASCO-CAP 2023 HER2-low/ultralow reclassification + T-DXd DB04/06 — dismantled the traditional “HER2-negative” category into three layers: 3+/2+ FISH+ / 1+ / 2+ FISH- / > 0 but < 1+ / true-negative — giving new targeted pathways to 60–70% of patients previously treated TNBC-like.

These four resonances together explain: the adjuvant or 1L decision for a newly diagnosed breast cancer in 2026 has 3 more decision layers than in 2016 (HR + HER2 four-tier → PIK3CA + BRCA + CPS → CDK4/6 adjuvant intensity choice → China-accessibility branch).

6. Full Trial Index

All 86 landmark trials listed by subtype and ascending year, with one-sentence positioning. Each trial’s detail page lives at /en/trials/breast/<trial_id>/, with click-through links to PubMed / ClinicalTrials.gov.

HR+/HER2- (29 trials)

MA.17 (letrozole extension post-tamoxifen × 5 years)
ATAC (anastrozole vs tamoxifen, 10-year DFS 79.9% vs 77.6%)
BOLERO-2 (everolimus + exemestane post-AI resistance)
ATLAS (tamoxifen 10 vs 5 years, OS benefit)
SOFT (premenopausal OFS + AI, high-risk adjuvant)
TEXT (SOFT’s twin, OFS + AI premenopausal)
PALOMA-3 (palbociclib + fulvestrant 2L post-endocrine)
PALOMA-2 (palbociclib + letrozole 1L mBC)
MONALEESA-2 (ribociclib + letrozole 1L postmenopausal)
MONARCH-2 (abemaciclib + fulvestrant 2L)
MONARCH-3 (abemaciclib + AI 1L)
TAILORx (Oncotype DX N0 RS 11–25 chemo sparing)
MONALEESA-3 (ribociclib + fulvestrant 1/2L)
MONALEESA-7 (ribociclib + OFS premenopausal)
SOLAR-1 (alpelisib + fulvestrant PIK3CAmut 2L)
monarchE (abemaciclib × 2 years adjuvant N ≥ 4 or 1–3+ high-risk)
RxPONDER (Oncotype N1 pre/postmenopausal stratification)
DAWNA-1 (dalpiciclib + fulvestrant 2L, China-originated)
EMERALD (elacestrant oral SERD ESR1mut 2L post-CDK4/6)
CAPItello-291 (capivasertib + fulvestrant AKT pathway alterations)
PADA-1 (ctDNA-driven ESR1mut switch feasibility)
DAWNA-2 (dalpiciclib + letrozole 1L, China)
NATALEE (ribociclib × 3 years adjuvant node-any stage IIA-III)
postMONARCH (abema + fulv continued post-CDK4/6 resistance)
INAVO120 (inavolisib + palbo + fulv PIK3CAmut 1L, mPFS 15.0 months)
SONIA (CDK4/6 at 1L vs 2L sequencing strategy trial)
SERENA-6 (camizestrant ctDNA-guided ESR1mut switch)
EMBER-3 (imlunestrant ± abemaciclib)
BG01-2201L (Chinese SERD data extension)

HER2+ (30 trials)

HERA (trastuzumab × 1 year adjuvant vs observation, 2005 NEJM)
NSABP B-31 / NCCTG N9831 joint (2005 NEJM, adjuvant)
EGF104900 (lapatinib + trastuzumab dual-target, later lines)
BCIRG-006 (TCH vs AC-TH, anthracycline-sparing adjuvant)
NeoSphere (dual-target + docetaxel neoadj pCR 45.8%)
CLEOPATRA (P + T + docetaxel 1L mBC, ten-year standard; Swain 2015 OS update)
EMILIA (T-DM1 vs lapatinib + capecitabine 2L)
TRYPHAENA (TCHP neoadj safety)
TH3RESA (T-DM1 3L+)
APT (T+H × 12 weeks low-risk HER2+ de-escalation)
ExteNET (neratinib extended adjuvant)
APHINITY (pertuzumab added to adjuvant HER2+)
MARIANNE (T-DM1 ± pertuzumab vs THx 1L, negative)
KRISTINE (T-DM1 + P neoadj vs TCHP, negative)
KATHERINE (non-pCR → T-DM1 adjuvant, iDFS HR 0.50)
PHENIX (pyrotinib + capecitabine 2L, China)
DESTINY-Breast01 (T-DXd 2L+ HER2+ mBC, accelerated 2020)
HER2CLIMB (tucatinib + T + cape, active brain mets)
HOPES (China HER2+ TKI + chemo)
PHOEBE (pyrotinib vs lapatinib 2L+ China 2021)
DESTINY-Breast03 (T-DXd vs T-DM1 2L HER2+ mPFS 28.8 vs 6.8 months)
TUXEDO-1 (T-DXd in active brain mets, Phase II)
ATEMPT (T-DM1 adjuvant low-risk HER2+ vs THx)
DESTINY-Breast02 (T-DXd post-T-DM1)
PHILA (pyrotinib + T + docetaxel 1L HER2+, China)
DEBBRAH (T-DXd brain-met evidence)
SHR-A1811-102 (China-originated HER2 ADC post-T-DM1, Phase II)
DESTINY-Breast09 (T-DXd + P 1L HER2+ mBC, CLEOPATRA challenger)

HER2-low / HER2-ultralow ADC (5 trials)

RC48-C006 (disitamab vedotin, China’s first domestic ADC)
DESTINY-Breast04 (T-DXd in HER2-low mBC, mPFS 10.1 vs 5.4 months)
MRG002-HER2low (China-originated ADC in HER2-low)
SHR-A1811-HER2low (China-originated ADC in HER2-low, Phase II)
DESTINY-Breast06 (T-DXd in HER2-ultralow 1L endocrine-resistant)

TNBC / BRCA · IO + PARP + TROP2 ADC (22 trials)

BEATRICE (bevacizumab adjuvant TNBC, negative)
GeparSixto (carbo neoadj TNBC pCR improvement)
CALGB-40603 (carbo neoadj TNBC pCR)
LOTUS (ipatasertib + paclitaxel 1L mTNBC)
BrighTNess (carbo + veliparib + pac neoadj TNBC)
IMpassion130 (atezo + nab-pac 1L mTNBC PD-L1+, mOS 25 months)
GeparNuevo (durvalumab + neoadj chemo TNBC)
KEYNOTE-522 (pembro + chemo neoadj → adj stage II-III TNBC, EFS HR 0.63 / OS HR 0.66)
IMpassion031 (atezo + chemo neoadj TNBC pCR benefit)
KEYNOTE-355 (pembro + chemo 1L mTNBC CPS ≥ 10, mOS 23 months)
KEYNOTE-158 (pembro MSI-H basket, includes breast)
PAKT (capivasertib + pac 1L mTNBC)
IMpassion131 (atezo + pac, negative)
ASCENT (sacituzumab govitecan 2L+ mTNBC, HR 0.48)
KEYNOTE-119 (pembro monotherapy 2L+ mTNBC, negative)
NeoTRIP (atezo neoadj TNBC)
FUTURE-SUPER (Fudan umbrella, LAR/BL1/IM/MES subtype matching)
TORCHLIGHT (toripalimab + nab-pac 1L mTNBC, China 2023)
CAMBRIA (camrelizumab + chemo neoadj, China)
ASCENT-04 (sacituzumab + pembro 1L PD-L1+ mTNBC)
TROPION-Breast02 (Dato-DXd 1L mTNBC vs TPC)
OlympiAD (olaparib 2L+ gBRCA mBC)

Cross-subtype (all breast cancer) · PARP adjuvant (2 + 1 cross-subtype adjuvant)

EMBRACA (talazoparib 2L+ gBRCA mBC)
OlympiA (olaparib × 1 year adjuvant gBRCA HER2- high risk, iDFS HR 0.58 / OS HR 0.68)

Key Research Gaps (10 excerpts)

monarchE vs NATALEE head-to-head missing: 2-year abemaciclib (N ≥ 4 or 1–3+ high-risk) vs 3-year ribociclib (node-any stage IIA-III) with no RCT — clinicians are forced into cross-trial choice.
Clinical meaning of continuing CDK4/6 after CDK4/6 resistance: is postMONARCH’s mPFS 6.0 vs 5.3 months enough to justify 6–8 months more toxicity exposure post-progression?
HER2-low / ultralow testing reproducibility: IHC 0 vs 1+ kappa ~0.6 — should dual pathologist validation be mandatory before T-DXd decision?
KN-522 adjuvant pembro de-escalation: do TNBC patients achieving pCR still need 1 year of pembro? The de-escalation trial is still being designed.
ADC sequencing: T-DXd → Dato-DXd → sacituzumab govitecan — is the resistance mechanism target downregulation or payload cross-resistance? Real-world molecular data is insufficient.
IO-chemo backbone in TNBC neoadj: IMpassion130 vs 131 chemo backbone mystery (atezo + nab-pac vs atezo + pac) is unattributed.
LAR / BL1 / IM / MES international replication: the reproducibility of Fudan TNBC four-subtype FUTURE-SUPER results in international populations is pending.
CDK4/6 adjuvant biomarker: multiple stratification tools (Ki67 + 21-gene + IHC4 + CTS5) were not prospectively isolated in monarchE / NATALEE subgroup analyses.
Premenopausal HR+ SOFT/TEXT vs simple tamoxifen: is OFS + AI over-treatment in low-Ki67 patients?
HER2+ active brain mets — T-DXd vs tucatinib vs RT integration: the three axes have not been systematically stratified; TUXEDO-1 / DEBBRAH / HER2CLIMB extended integration data has not yet formed a unified algorithm.

7. Sources & Methodology

All 86 trials indexed in this overview come from data/trials/breast.yaml, extracted by 4-way parallel subagents (A HR+/HER2- · B HER2+ · C TNBC · D China-lead) from NCCN Breast Cancer v2.2026 primary source + NMPA / CSCO / ESMO Asia abstracts, bilingual fields completed by translate-trials.py, and rendered into the static site via Hugo.

7.1 Pivotal trial PMID inventory

PMID backfill uses a three-filter pipeline: NCT [si] tag-based PubMed esearch + year/journal hard match + breast keyword title guard — name-based fallback is prohibited (lesson from the 58% fabrication rate of agent “best-effort PMID” in early 2026-04). Of the 86 trials, 55 received verified PMIDs (pilot 5/5 + random spot-check 10/10 = 0% fab rate); 31 remain null (ASCO/ESMO abstract-only 7 · NCT not [si] indexed 9 · year/journal mismatch 11 · ambiguous 4). Inline PubMed hyperlinks are now in place in the §2–§5 narrative for trials with PMIDs — click [Year Journal] to jump to the PubMed primary publication. Full per-trial PMID + source-ref is on /en/trials/breast/<trial_id>/.

HR+/HER2- (29 trials):

MA.17 · ATAC · BOLERO-2 · ATLAS · SOFT · TEXT · PALOMA-3 · PALOMA-2 · MONALEESA-2 · MONARCH-2 · MONARCH-3 · TAILORx · MONALEESA-3 · MONALEESA-7 · SOLAR-1 · monarchE · RxPONDER · DAWNA-1 · EMERALD · CAPItello-291 · PADA-1 · DAWNA-2 · NATALEE · postMONARCH · INAVO120 · SONIA · SERENA-6 · EMBER-3 · BG01-2201L

Among these, the 2023–2025 new arrivals (CAPItello-291 / EMERALD / NATALEE / INAVO120 / SERENA-6 / EMBER-3 / postMONARCH / BG01-2201L) form the newest 8-trial pivotal evidence chain in HR+/HER2- precision therapy.

HER2+ / HER2-low (33 trials):

HERA · NSABP B-31·N9831 · EGF104900 · BCIRG-006 · NeoSphere · CLEOPATRA · EMILIA · TRYPHAENA · TH3RESA · APT · ExteNET · APHINITY · MARIANNE · KRISTINE · KATHERINE · PHENIX · DESTINY-Breast01 · HER2CLIMB · HOPES · PHOEBE · DESTINY-Breast03 · TUXEDO-1 · ATEMPT · DESTINY-Breast02 · PHILA · DEBBRAH · SHR-A1811-102 · DESTINY-Breast09 · RC48-C006 · DESTINY-Breast04 · MRG002-HER2low · SHR-A1811-HER2low · DESTINY-Breast06

The DESTINY-Breast family 01–09 + RC48 / SHR-A1811 / MRG002 form the 10-trial pivotal chain of ADC reshaping — the most dramatic drug-class change in the breast cancer landscape from 2020–2025.

TNBC / BRCA (24 trials):

BEATRICE · GeparSixto · CALGB-40603 · LOTUS · BrighTNess · IMpassion130 · GeparNuevo · KEYNOTE-522 · IMpassion031 · KEYNOTE-355 · KEYNOTE-158 · PAKT · IMpassion131 · ASCENT · KEYNOTE-119 · NeoTRIP · FUTURE-SUPER · TORCHLIGHT · CAMBRIA · ASCENT-04 · TROPION-Breast02 · OlympiAD · EMBRACA · OlympiA

KEYNOTE-522 (stage II-III TNBC EFS / OS dual benefit) + ASCENT (sacituzumab govitecan 2L+ mOS 12.1 months) + OlympiA (gBRCA HER2- adjuvant iDFS benefit) form the TNBC three pillars of the past 5 years, paired with Fudan’s LAR/BL1/IM/MES molecular subtyping and China’s TORCHLIGHT / CAMBRIA domestic IO combinations — shaping the global TNBC treatment landscape’s main trunk.

7.1.1 Phase III trials in progress (2025–2027 expected readouts, curated)

Ten selected readouts from breast 2025–2027 Phase III pipeline that are “likely to change practice”:

DESTINY-Breast05 (T-DXd vs T-DM1 adjuvant high-risk non-pCR HER2+) — if positive, KATHERINE’s T-DM1 adjuvant standard hands over.
DESTINY-Breast11 (T-DXd adjuvant earlier-stage HER2+)
DESTINY-Breast12 (T-DXd mBC CNS-preserving subset)
PATINA (palbociclib + endocrine + trastuzumab maintenance HR+ HER2+ mBC)
TROPION-Breast03 (Dato-DXd 2L mTNBC post-ASCENT)
ASCENT-03 / 05 (sacituzumab govitecan expansion to more settings)
KEYNOTE-522 adjuvant de-escalation (ongoing)
RASTRUM / CTDX series (ctDNA-guided adjuvant / switch)
PIK3CA genotype 1L head-to-head (inavolisib vs alpelisib)
FUTURE-C series (Fudan TNBC subtype umbrella extension)

7.2 Guideline citation

NCCN Clinical Practice Guidelines in Oncology · Breast Cancer · V2.2026 (Feb 27, 2026) — primary source; this post’s 7-chapter skeleton and subtype stratification are aligned with that version.
ASCO-CAP 2023 HER2 testing updates — HER2-low / HER2-ultralow definitions and testing guidance.
FDA approval letters + NMPA drug approval announcements — public-domain regulatory reference.
Fudan University Zhongshan Hospital TNBC molecular subtyping series (Shao Z-M team, LAR / BL1 / IM / MES, FUTURE series umbrella trials) — China’s original contribution to TNBC precision subtyping.

7.3 Methodology

This overview is produced by a clinical-trials pipeline: 4-way parallel subagent extract (A HR+/HER2- · B HER2+ · C TNBC · D China-lead hunt) × NCCN Breast Cancer v2.2026 primary source × translate-trials.py (B8 upgraded auto-retry, 0% fail rate) × Hugo static render. 86 trials × 4 bilingual fields per trial (interventional arm · comparator arm · key finding · clinical relevance) × 0 schema drift.

Breast is the first tumor type where the pipeline introduces subtype-stratified content expansion (L2 H3 three-split) — a template candidate for future multi-subtype tumors such as lymphoma / sarcoma. The PMID backfill backlog completed on 2026-04-22 (NCT [si] hunt + 3-filter gate + 5-gate ladder + 0% fabrication rate over 15 spot-checks); see memory/data-pipeline-patterns.md §6 for methodology.

Takeaways for junior-to-mid-level oncologists:

“Test panel first, then decide” is now standard of care. In 2026, entering treatment decisions without having tested HR / HER2 (including low/ultralow tiers) / gBRCA / PIK3CA is wrong. Missing HER2-low means missing DB04/06 T-DXd; missing gBRCA means missing OlympiA adjuvant and OlympiAD/EMBRACA in advanced disease; missing PIK3CA means missing INAVO120’s 1L increment.
Premenopausal HR+ N+ high-risk: always consider OFS + AI (SOFT/TEXT), don’t default to tamoxifen.
Choose monarchE vs NATALEE by enrollment risk: N ≥ 4 → monarchE evidence is stronger; 1–3+ high-risk features can go monarchE; stage IIA node-any wanting adjuvant CDK4/6 can only go NATALEE.
HER2+ non-pCR post-neoadjuvant: always switch to T-DM1 (KATHERINE) — don’t continue trastuzumab.
HER2+ mBC 2L first choice is T-DXd (DESTINY-Breast03); T-DM1 in 2L now hands over when T-DXd is accessible.
HER2+ active brain mets → HER2CLIMB (tucatinib regimen), don’t use the old lapatinib + capecitabine.
TNBC stage II-III all-comer KEYNOTE-522 regimen (no PD-L1 screening); but don’t apply KN-522 to stage I small tumors — avoid over-treatment.
mTNBC 1L: check CPS first. CPS ≥ 10 → pembro + chemo; CPS < 10 and gBRCA+ → consider PARP; otherwise → chemo backbone.
All HER2-, germline BRCA1/2 is mandatory testing — it drives adjuvant (OlympiA) + advanced (OlympiAD / EMBRACA) + TNBC fertility decisions.
China-originated drugs are reasonable alternatives under reimbursement-accessible scenarios: dalpiciclib / pyrotinib / disitamab vedotin / toripalimab / camrelizumab — their Phase III data stand independently, and price × accessibility is the main driver of insurance-coverage decisions.

This post is a 2026-04-22 snapshot; it does not substitute for clinical judgment. Each trial’s specific use setting should defer to NCCN v2.2026 / CSCO 2025 / drug label / local reimbursement availability.

Clinical Trials Timeline

Chinese: /trials/breast/ English: /en/trials/breast/

Each trial has an independent detail page containing:

Full intervention / comparator regimen.
Primary endpoint numerical values + 95% CI.
Key findings + clinical significance.
Click-through links to NCT / PMID source.

86 trials · 4 subtype groups · 1995 to 2025 · global multi-center + China-originated contributions · NCCN v2.2026 aligned.

Closing

Over the past 25 years, breast cancer has been oncology’s most extensively subtyped, most fully equipped, and most divergent-by-subtype tumor type. From ER’s discovery in 1975, HER2’s identification in 1987, to TNBC’s naming in 2005, the three-pillar framework was established — then in 2023 ASCO-CAP split out HER2-low / HER2-ultralow. Categories finer, therapy more precise.

All five paradigms reached maturity simultaneously in 2020–2025. ADC reshaping (DESTINY series + TROP2 ADC) is the headline act: T-DXd pushed HER2+ 2L mPFS from 6.8 to 28.8 months (HR 0.33) via DESTINY-Breast03 in 2022, and in 2025 DESTINY-Breast09 began challenging CLEOPATRA’s ten-year iron throne at 1L; sacituzumab govitecan / Dato-DXd gave TNBC — traditionally the “only chemo” hardest subtype — its first targeted pathway. China-originated ADCs (SHR-A1811 / MRG002 / RC48) and CDK4/6 (dalpiciclib DAWNA series) advance in parallel with the international track, taking ~20% of NMPA oncology approvals in 2025.

HR+/HER2-, the largest-share (65–70%) subtype, completed four-generation leaps over the same period: CDK4/6 pushed advanced 1L mPFS from 9–14 months to 24–28 months (PALOMA / MONALEESA / MONARCH families); monarchE / NATALEE pushed CDK4/6 into adjuvant; INAVO120 / SERENA-6 / CAPItello-291 layered precision by PIK3CA / ESR1 / AKT. Premenopausal high-risk adjuvant uses OFS + AI (SOFT / TEXT); postmenopausal extends AI to 10 years (MA.17R) — the endocrine backbone was not replaced but became the increasingly precise foundation of combinatorial layering.

TNBC, the 10–15%-share but “hardest to treat” subtype, in 5 years climbed out of the “only chemo” isolation: KEYNOTE-522 standardized IO + chemo as the stage II-III TNBC neoadjuvant backbone; ASCENT placed sacituzumab govitecan in 2L+ advanced; OlympiA extended PARP to gBRCA HER2- high-risk adjuvant; Fudan Shao’s LAR / BL1 / IM / MES four-subtype + FUTURE-SUPER umbrella is China’s original contribution to TNBC molecular subtyping on the international scene; TORCHLIGHT / CAMBRIA give China independent IO data. TNBC’s 2026 landscape change magnitude is the largest in the past 20 years.

This overview’s value is not in exhaustively enumerating 86 trials (/trials/breast/ does that) but in compressing the crossed structure of 25 years × three-subtype three-world × five-paradigm rotation × ADC reshaping into a single reading’s cognitive bandwidth. The next time you face a newly diagnosed breast cancer patient — HR / HER2 / TNBC branching + neoadj / adj / advanced pathways + five-paradigm anchoring — every layer of the decision tree has this map to consult, trace, and question.

Each of the 86 trials has a name + time + scenario + conclusion. Stitched together, they form the 1990–2025 breast cancer treatment evolution map. ADC reshaping’s headline act has just opened its first page; the chapters of DB09 / DB11 / TROPION-Breast series are still unfolding; ctDNA-guided precision therapy is spreading to more settings after SERENA-6; the optimal duration and biomarker stratification of CDK4/6 adjuvant are still under discussion.

Clinician × AI = Research Superpower + Clinical Decision Amplifier